Biogen (NASDAQ:BIIB) Price Target Raised to $215.00

Biogen (NASDAQ:BIIB) had its price target raised by research analysts at Citigroup from $185.00 to $215.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. Citigroup’s price target would suggest a potential upside of 9.81% from the company’s current price.

Several other brokerages have also recently commented on BIIB. The Goldman Sachs Group reissued a “buy” rating and set a $225.00 target price on shares of Biogen in a report on Thursday, January 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th. TD Cowen reaffirmed a “buy” rating and set a $215.00 target price (up previously from $175.00) on shares of Biogen in a research note on Monday. Guggenheim boosted their price target on shares of Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Robert W. Baird cut their price target on shares of Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Thirteen equities research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. According to MarketBeat.com, Biogen currently has a consensus rating of “Hold” and an average price target of $205.30.

Biogen Price Performance

BIIB stock traded down $5.40 during trading on Monday, hitting $195.79. The company had a trading volume of 610,366 shares, compared to its average volume of 1,640,478. The business has a 50 day moving average of $176.94 and a 200 day moving average of $157.05. The firm has a market capitalization of $28.72 billion, a price-to-earnings ratio of 22.21, a P/E/G ratio of 1.70 and a beta of 0.16. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $202.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s revenue was down 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, research analysts predict that Biogen will post 15.83 earnings per share for the current year.

Insider Activity at Biogen

In other Biogen news, insider Priya Singhal sold 748 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $179.30, for a total value of $134,116.40. Following the completion of the transaction, the insider directly owned 6,271 shares in the company, valued at $1,124,390.30. This trade represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.18% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Biogen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Biogen in the 2nd quarter valued at approximately $284,358,000. Orion Porfolio Solutions LLC increased its stake in shares of Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after purchasing an additional 509,809 shares during the last quarter. Caisse de depot et placement du Quebec lifted its stake in shares of Biogen by 718.2% in the 3rd quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock valued at $79,741,000 after purchasing an additional 499,676 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Biogen by 30.7% in the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after purchasing an additional 418,776 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Biogen by 190.7% in the second quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock worth $78,415,000 after purchasing an additional 409,591 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance — Biogen reported Q4 EPS and revenue above estimates and set FY2026 EPS guidance well above Street expectations, driving investor optimism about near-term profitability and demonstrating stabilization after recent headwinds. Biogen Posts Q4 Beat, Analysts Raise Price Targets On ‘Significant Pipeline Diversification’
• Positive Sentiment: Analyst upgrades / higher targets — Several firms (RBC, HC Wainwright, others) raised price targets and reiterated buys/outperform ratings after the print, signaling dealer confidence in upside tied to LEQEMBI traction and cash flow. RBC Raises Price Target on Biogen to $233 From $217
• Positive Sentiment: Regulatory progress for LEQEMBI — The biologics license application for a subcutaneous formulation of LEQEMBI has been designated for priority review, which could expand the drug’s market and ease administration logistics if approved. Biologics License Application for Subcutaneous Formulation of “LEQEMBI” Designated for Priority Review
• Positive Sentiment: Commercial momentum — Reports show LEQEMBI sales jumped and the stock hit a 52‑week high on the strength of Alzheimer’s drug demand, supporting the thesis that new revenue streams are offsetting declines elsewhere. Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
• Neutral Sentiment: Mixed analyst stance — Several firms raised price targets but kept neutral/hold ratings (Piper Sandler, Wedbush, Truist, Morgan Stanley, UBS), reflecting disagreement on sustainable growth and execution risk despite the beat. Piper Sandler Raises Price Target
• Negative Sentiment: MS franchise pressure — Core multiple sclerosis product sales declined and were cited on the call and in coverage as a continuing drag on revenue; investors may worry about duration and magnitude of that erosion. Biogen Revenue Down as Multiple Sclerosis Sales Slide (WSJ)
• Negative Sentiment: Execution and growth risk flagged by analysts — Deeper-dive commentary (Seeking Alpha and others) highlights MS weakness and the high-risk nature of pipeline bets, which could cap valuation if LEQEMBI uptake or new approvals slow. Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.